24-Week efficacy and safety results from the adalimumab effectiveness in psoriatic arthritis trial (ADEPT)

被引：0
|
作者：
Mease, PJ
Choy, EHS
Gladman, DD
Ritchlin, CT
Ruderman, EM
Steinfeld, SD
Weinberg, MA
机构：
[1] Univ Washington, Sch Med, Seattle, WA USA
[2] Univ London Kings Coll, London WC2R 2LS, England
[3] Univ Toronto, Toronto, ON, Canada
[4] Univ Rochester, Sch Med & Dent, Rochester, NY USA
[5] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
[6] Erasme Univ Hosp, B-1070 Brussels, Belgium
[7] Abbott Labs, Abbott Pk, IL 60064 USA
来源：
RHEUMATOLOGY | 2005年 / 44卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
OP5
引用
收藏
页码：I3 / I3
页数：1
相关论文
共 50 条
  • [1] Clinical efficacy and safety of adalimumab for psoriatic arthritis: 48-week results of ADEPT
    Mease, PJ
    Gladman, DD
    Ritchlin, CT
    Ruderman, EM
    Choy, EHS
    Steinfeld, SD
    Perdok, R
    Sasso, EH
    Weinberg, MA
    ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S215 - S215
  • [2] Adalimumab in psoriatic arthritis: 24-week results of a phase III study
    Mease, P
    Gladman, D
    Ritchlin, C
    Weinberg, M
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 52 (03) : P2 - P2
  • [3] Adalimumab therapy in patients with psoriatic arthritis: 24-week results of a phase III study
    Mease, PJ
    Gladman, DD
    Ritchlin, CT
    Ruderman, EM
    Steinfeld, SED
    Choy, EHS
    Perdok, RJ
    Weinberg, TA
    ARTHRITIS AND RHEUMATISM, 2004, 50 (12): : 4097 - 4097
  • [4] Clinical efficacy, safety and inhibition of joint destruction of adalimumab in the treatment of moderate to severe psoriatic arthritis: 48-week results of the ADEPT trial
    Mease, P
    Gladman, D
    Ritchlin, C
    Weinberg, M
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 54 (03) : AB214 - AB214
  • [5] Long-term efficacy, safety, and inhibition of joint destruction by adalimumab in psoriatic arthritis: Results from ADEPT
    Mease, Philip J.
    Gladman, Dafna
    Ritchlin, Christopher
    Sasso, Eric
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2007, 127 (07) : 1820 - 1820
  • [6] Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial
    Kristensen, Lars Erik
    Keiserman, Mauro
    Papp, Kim
    McCasland, Leslie
    White, Douglas
    Lu, Wenjing
    Wang, Zailong
    Soliman, Ahmed M.
    Eldred, Ann
    Barcomb, Lisa
    Behrens, Frank
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (02) : 225 - 231
  • [7] Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial
    Ostor, Andrew
    Van den Bosch, Filip
    Papp, Kim
    Asnal, Cecilia
    Blanco, Ricardo
    Aelion, Jacob
    Alperovich, Gabriela
    Lu, Wenjing
    Wang, Zailong
    Soliman, Ahmed M.
    Eldred, Ann
    Barcomb, Lisa
    Kivitz, Alan
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (03) : 351 - 358
  • [8] Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)
    Mease, P. J.
    Ory, P.
    Sharp, J. T.
    Ritchlin, C. T.
    Van den Bosch, F.
    Wellborne, F.
    Birbara, C.
    Thomson, G. T. D.
    Perdok, R. J.
    Medich, J.
    Wong, R. L.
    Gladman, D. D.
    ANNALS OF THE RHEUMATIC DISEASES, 2009, 68 (05) : 702 - 709
  • [9] Efficacy of adalimumab by disease duration in psoriatic arthritis: Subanalysis of ADEPT
    Choy, Ernest
    Gladman, Dafna
    Sasso, Eric
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2007, 56 (02) : AB186 - AB186
  • [10] Adalimumab for long-term treatment of psoriatic arthritis - Forty-eight week data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial
    Gladman, Dafna D.
    Mease, Philip J.
    Ritchlin, Christopher T.
    Choy, Ernest H. S.
    Sharp, John T.
    Ory, Peter A.
    Perdok, Renee J.
    Sasso, Eric H.
    ARTHRITIS AND RHEUMATISM, 2007, 56 (02): : 476 - 488
12345